Bayer Initiates Phase IIa ASSESS Trial of Investigational Antibody BAY 3401016 for Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...

December 05, 2025 | Friday | News
LabGenius Therapeutics Announces Second Collaboration With Sanofi to Co-Optimise Therapeutic NANOBODY® Molecules

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to o...

December 05, 2025 | Friday | News
Taiho Oncology Europe Announces UK Launch of Lytgobi (Futibatinib) for Eligible Patients With Locally Advanced or Metastatic Cholangiocarcinoma

Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...

December 04, 2025 | Thursday | News
MUVON Therapeutics Reports Positive Topline Results From Phase 2 SUISSE-MPC2 Trial of MPC-Based Therapy in Female Stress Urinary Incontinence

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT0553...

December 04, 2025 | Thursday | News
Onco3R Therapeutics Completes Dosing of First MAD Cohort in Phase 1 Trial of O3R-5671 With No Drug Related Adverse Events

Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life...

December 04, 2025 | Thursday | News
VANUDIS Implements Cenevo Labguru to Scale Operations and Strengthen Regulatory Readiness

VANUDIS, a biotechnology startup developing the next generation of antibody-based therapeutics, has implemented Cenevo’s Labguru solution to scale ...

December 04, 2025 | Thursday | News
Kuros Biosciences Begins Enrollment in Global ASTRA Trial as Part of Expanding Extremities Strategy

Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies,  announced that the first patient...

December 03, 2025 | Wednesday | News
Roche’s 15-Minute PCR Test for Whooping Cough Receives FDA Clearance and CLIA Waiver

The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications ...

December 02, 2025 | Tuesday | News
Bavarian Nordic Announces Intention to Launch DKK 500 Million Share Buy-Back Program

Bavarian Nordic A/S  announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 month...

December 03, 2025 | Wednesday | News
VNA-318 Demonstrates Strong Target Engagement and Safety in First-in-Human Trial

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...

December 03, 2025 | Wednesday | News
Rentschler Biopharma and Coriolis Pharma Announce Strategic Collaboration to Deliver Seamless, End-to-End Biopharmaceutical Development Solutions

The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chain Clien...

December 03, 2025 | Wednesday | News
Ensoma Launches First-In-Human Study of EN-374 Offering New Hope for People With X-Linked CGD

First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chroni...

December 02, 2025 | Tuesday | News
Arletta Pharma Emerges from Freya Pharma Rebranding to Focus on Women’s Sexual Health

New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...

December 01, 2025 | Monday | News
Kedrion Secures EMA Orphan Drug Designation for Investigational Aceruloplasminemia Therapy

  Kedrion announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its investigational treatment for Congenita...

November 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close